Page 394 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

372 PART IV Specific Malignancies in the Small Animal Patient

TABLE 20.1 Published Studies on the Treatment of Oral Melanoma with Radiation Therapy
Study, Study Type Source and Dose/Protocol of
VetBooks.ir (Year Published) Species (No.) Radiation Outcomes Chemotherapy

Bateman et al, Prospec-
tive single-arm trial Canine (18) Cobalt-60; 24 Gy in three once- One dog died during treatment,
9/18 had a complete response,
weekly fractions of 8 Gy.
(1994) 137 5/18 had a partial response,
3/18 had no response, MST:
7.9 months.
Blackwood et al, Prospec- Canine (36) 4 MV linear accelerator (n = 29), 25/36 dogs had a complete
tive single-arm trial 250 kVp orthovoltage unit response, 9/36 had a partial
(1996) 138 (n = 1), combination of the response, overall MST not
two machines (n = 4) 36 Gy reported (range, 5–213
in four once-weekly fractions weeks), MST for dogs that
of 9 Gy. died of tumor-related causes:
21 weeks.
Theon et al, Prospec- Canine (38) Cobalt-60; 48 Gy in 12 4-Gy PFS 7.9 months, MST not
tive single-arm trial fractions on a Monday– reported.
(1997) 108 Wednesday–Friday schedule.
Proulx et al, Retrospective Canine (140) Cobalt-60: 36 Gy in four once 45/86 dogs had a complete 80 dogs received chemotherapy
case series (2003) 107 weekly 9-Gy fractions response and 27/86 dogs had (carboplatin [n = 60], cisplatin
(n = 54); 30 Gy in 3 once- a partial response. Median [n = 3], melphalan [n = 17]).
weekly 10-Gy fractions time to first event (metastasis, Chemotherapy did not affect
(n = 69), or 45.6–57 Gy in local recurrence, or death): 5.0 time to first event or survival.
12 to 19 2–4 Gy fractions months, MST: 7.0 months.
(n = 17).
Freeman et al, Retro- Canine (39) Cobalt-60 and 4 MV linear MST: 363 days. Dogs received cisplatin (10–
spective case series accelerator: 36 Gy in 6 once- 30 mg/m IV) or carboplatin
2
(2003) 106 weekly 6-Gy fractions. (90 mg/m IV) chemotherapy
2
60 minutes before radiation
delivery.
Farrelly et al, Retro- Feline (5) Cobalt-60: 24 Gy in three once- One complete response, two Two cats received chemotherapy,
spective case series weekly 8-Gy fractions. partial responses, MST: one received carboplatin, one
(2004) 26 146 days. carboplatin and mitoxantrone,
and one was treated with a
DNA-based vaccine.
One cat had additional radiation
after initial failure.
Murphy et al, Retrospec- Canine (28) 4 MV linear accelerator: 36 Gy No chemotherapy group, MST No chemotherapy, 13 dogs.
tive two-arm study in four once weekly 9-Gy 307 days. Chemotherapy group, 15 dogs
(2005) 139 fractions. Chemotherapy group, MST treated with carboplatin
2
286 days. (planned dose: 300 mg/m IV
every 21 days).
Dank et al, Retrospective Canine (17); 11 Radiotherapy sources not PFS radiotherapy group, 259 Carboplatin (median dose of 300
2
case series (2012) 135 dogs treated indicated. 32 Gy in four once- days; PFS no radiotherapy mg/m IV).
with surgery, weekly 8-Gy fractions (n = group, 210 days. MST radio-
chemotherapy, 5), 36 Gy in six twice-weekly therapy group, 440 days; MST
and radiation; 6-Gy fractions (n = 4), 30 Gy no radiotherapy group, 387
6 dogs treated in three once-weekly 10-Gy days. No significant difference
with surgery and fractions (n = 1), and 24 Gy in between groups.
chemotherapy four once-weekly 6-Gy frac-
tions (n = 1).
Kawabe et al, Retro- Canine (111) Orthovoltage 300 Kvp (n = 68), 4 38/87 dogs had a complete 66 dogs had chemotherapy:
spective case series MV linear accelerator (n = 34) response and 36/87 dogs had either intralesional cisplatin
(2015) 140 or combined (n = 5); electron a partial response. MST: 171 (0.5mg/dog q1–2wks; n = 26),
therapy, energy not reported days; MST for orthovoltage- carboplatin IV (180–250 mg/
2
(n = 4). The median total treated dogs, 122 days; MST m q3wks; n = 26), or both
radiation dose was 37.8 Gy for megavoltage-treated dogs, (n = 14).
(range, 6.3–74.3 Gy). 233 days. This was statistically
different.